Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Berry-Kravis

Neurology with Special Qualifications in Child Neurology Chicago, IL Medical Doctor

NPI 1932130325 CMS profile 389553

1725 W Harrison St, Suite 710, Chicago, IL 60612

Open in the dashboard

General payments

$37,762

63 records reported · program years 2019–2025

Research payments

$11,681

Paid to them · 35 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,697,736 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Elizabeth Berry-Kravis of Chicago, IL is reported in the CMS Open Payments database as having received $37,762 across 63 general payments and $11,681 in research payments paid to them. Separately, studies naming them as principal investigator received $7,697,736 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,884 30
2024 General $1,278 3
2023 General $5,962 6
2023 Research $4,810 1
2022 General $7,098 4
2021 General $8,838 4
2020 General $4,374 4
2019 General $5,327 12
2019 Research $6,870 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Berry-Kravis
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Elizabeth Berry-Kravis were reported at $4,884. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Elizabeth Berry-Kravis Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $5,327 $262 $68–$1,313 $163
2020 $4,374 $188 $46–$1,222 $114
2021 $8,838 $183 $45–$1,356 $132
2022 $7,098 $229 $72–$1,177 $149
2023 $5,962 $269 $93–$1,195 $160
2024 $1,278 $300 $98–$1,428 $164
2025 $4,884 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $7,800 3 payments
  2. Roche Products Limited $7,663 7 payments
  3. F. Hoffmann-La Roche AG $5,226 6 payments
  4. Mallinckrodt Enterprises LLC $3,875 7 payments
  5. BioMarin Pharmaceutical Inc. $3,395 4 payments
  6. PTC Therapeutics, Inc. $2,700 1 payment
  7. Ultragenyx Pharmaceutical Inc. $2,042 3 payments
  8. Zevra Therapeutics Inc $1,800 1 payment
  9. Biogen, Inc. $1,561 2 payments
  10. Shionogi Inc $932 24 payments
  11. Other $766 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,523 18 payments
  2. Travel and Lodging $4,072 16 payments
  3. Education $3,257 2 payments
  4. Honoraria $1,800 1 payment
  5. Food and Beverage $1,110 26 payments
Products named General payments · program years 2019–2025
  1. Brineura $3,274 3 payments
  2. Olpruva $1,800 1 payment
  3. Non-Covered Product $1,440 1 payment
  4. BPN14770 $932 24 payments
  5. Fintepla $133 1 payment
  6. ACTHAR $59 1 payment
  7. AQNEURSA $49 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $6,870 34 payments
  2. F. Hoffmann-La Roche AG $4,810 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,355

Median for Psychiatry: 574

Drug cost

$265,512

Median for Psychiatry: $27,624

Branded share of claims

19.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xcopri Cenobamate Brand 55 $72,103
Epidiolex Cannabidiol (Cbd) Brand 20 $50,161
Briviact Brivaracetam Brand 24 $37,722
Aripiprazole Generic 189 $22,825
Rufinamide Generic 12 $21,601
Prozac Fluoxetine Hcl Brand 13 $18,254
Depakote Er Divalproex Sodium Brand 11 $9,220
Methylphenidate Er Methylphenidate Hcl Brand 41 $5,713
Lisdexamfetamine Dimesylate Generic 15 $3,699
Lacosamide Generic 37 $2,828

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$8,794

Medicare's payments for the services billed

Medicare patients

39

Average age 38

Services billed

127

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Ischemic heart disease 0%
Atrial fibrillation 0%
COPD 0%
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fintepla
  • UCB, Inc. $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record